title: Comparison of the effects of a 7-day period of non-compliance on blood pressure control using three different antihypertensive agents.
abstract: OBJECTIVE
  To compare blood pressure control during 7 days of drug omission in patients taking bendroflumethiazide 2.5 mg, nifedipine LA 30 mg or enalapril 20 mg once daily and, secondarily, to measure patient compliance.
  
  
  METHODS
  Twenty-four patients with hypertension were assigned, in a random crossover fashion, to a sequence of bendroflumethiazide, nifedipine LA and enalapril, each for 4 weeks, followed by a 1-week period of dose omission. The patients measured their own blood pressure daily using an Omron 705CP monitor. Differences in blood pressure from baseline (mean blood pressure during week 4 on treatment) and the week of dose omission were compared between the three drugs. Patient compliance was measured using pill counts and the Medication Event Monitoring System.
  
  
  RESULTS
  Bendroflumethiazide maintained blood pressure control during drug omission for longer than enalapril or nifedipine LA. The magnitudes of the increase in systolic blood pressure (SBP) between baseline and day 7 off treatment were 7.0, 12.2 and 9.7 mmHg for bendroflumethiazide, nifedipine LA and enalapril, respectively. For diastolic blood pressure (DBP), the values were 2.9, 5.3 and 7.3 mmHg for bendroflumethiazide, nifedipine LA and enalapril, respectively. Differences in SBP between bendroflumethiazide and the comparator drugs occurred at day 2 off treatment. Differences in DBP between bendroflumethiazide and nifedipine were apparent on days 2 and 3 off treatment. Differences in DBP between bendroflumethiazide and enalapril were apparent on days 2, 3, 4 and 5 off treatment. Patient compliance throughout the study was high in terms of both taking the medication when required and omitting the medication when required.
  
  
  CONCLUSIONS
  Bendroflumethiazide maintained blood pressure control during a period of drug omission better than nifedipine or enalapril.
authors.affiliation: Department of Therapeutics and Pharmacology, Queen's University Belfast, Belfast, Northern Ireland.
authors.forename: Briegeen G
authors.initials: BG
authors.lastname: Girvin
authors.forename: G Dennis
authors.initials: GD
authors.lastname: Johnston
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001539:Bendroflumethiazide / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D004656:Enalapril / Q000008:administration & dosage*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D009543:Nifedipine / Q000008:administration & dosage*; D012646:Self Administration; D016312:Treatment Refusal
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D001539:Bendroflumethiazide; D004656:Enalapril; D009543:Nifedipine